Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/25/2025 | $31.00 | Buy | Guggenheim |
| 9/20/2024 | $2.00 → $35.00 | Hold → Buy | Jefferies |
| 9/13/2021 | $3.50 | Neutral | HC Wainwright & Co. |
| 9/2/2021 | Outperform → Market Perform | William Blair |
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
-- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer. Dr. Gaggar is an infectious disease specialist and seasoned executive whose experience has focused on the development of new therapies in viral diseases including chronic hepatitis B virus (HBV), hepatitis C vi
−ABI-5366 Demonstrates Favorable Profile for a Long-Acting Therapeutic in Preclinical Studies −IND-Enabling Studies Initiating for 5366, Supporting Anticipated IND/CTA Filing in 1H2024 SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced the selection of development candidate ABI-5366 (5366) to progress to IND-enabling studies for its long-acting herpes simplex virus type 2 (HSV-2) helicase inhibitor program. 5366 is the first development candidate from Assembly Bio's discovery pipeline nominated for adv
Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB. Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D. "I am thrilled to have Dr. Lopatin, Dr. Merkel and Dr. Sanjana join our advisory board," said Dr. Walter Strapps, co-founder and CEO of Carver. "Along with Dr. Myhrvold, these scientific leaders will help us shape our pipeline and advance our programs into the clinic." Uri Lopatin, M.D. Dr. Lopatin is a serial biotech entrepreneur who founde
10-Q - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
DEFA14A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)
Guggenheim initiated coverage of Assembly Biosciences with a rating of Buy and set a new price target of $31.00
Jefferies upgraded Assembly Biosciences from Hold to Buy and set a new price target of $35.00 from $2.00 previously
HC Wainwright & Co. initiated coverage of Assembly Biosciences with a rating of Neutral and set a new price target of $3.50
SC 13G - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)
SOUTH SAN FRANCISCO, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that Jason Okazaki, chief executive officer and president, and Anuj Gaggar, MD, PhD, chief medical officer, will present in a fireside chat during the Jefferies 2025 Global Healthcare Conference at 8:45 a.m. Eastern Time on June 4, 2025. A live webcast will be available on the Events and Presentations section of Assembly Bio's website and a replay will be accessible following the event. To register for the live webcast and replay, please visit: https://investor.assemblybio.com/eve
– Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall 2025 – – New data from multiple programs highlighted at ICAR, ESCMID and EASL 2025 – SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results and recent updates for the first quarter ended March 31, 2025. "We continue the strong progress across our antiviral portfolio and remain on track for the multiple key clin
– Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline – – Interim Phase 1b proof-of-concept data, including initial efficacy measures, anticipated in fall 2025 for ABI-5366 and ABI-1179, long-acting helicase-primase inhibitor candidates for recurrent genital herpes – SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results for the year ended December 31, 2024, and recent highlights. "We are well-positioned to deliver important clinic